Gilead Sciences (GILD) Receivables (2009 - 2026)

Gilead Sciences (GILD) has reported Receivables for 18 consecutive years, with $5.9 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Receivables rose 4.96% year-over-year to $5.9 billion; the trailing twelve-month figure through Jun 2026 stood at $5.9 billion (up 4.96% YoY), and the FY2025 full-year result was $5.9 billion, up 10.83% from the prior year.
• Receivables improved to $5.9 billion in Q2 2026 per GILD's latest filing, from $5.5 billion in the prior quarter.
• Across five years, Receivables topped out at $6.0 billion in Q3 2025 and bottomed at $4.6 billion in Q1 2022.
• Historically, Receivables has averaged $5.4 billion across 5 years, with a median of $5.5 billion in 2022.
• The sharpest annual moves came in 2022 and 2024: Receivables fell 5.26% in 2022, then rose 11.86% in 2024.
• Over 5 years, Receivables stood at $5.5 billion in 2022, then advanced by 0.57% to $5.5 billion in 2023, then declined by 3.2% to $5.3 billion in 2024, then gained by 10.83% to $5.9 billion in 2025, then advanced by 0.12% to $5.9 billion in 2026.
• According to Business Quant data, Receivables over the past three periods registered $5.9 billion, $5.5 billion, and $5.9 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.